WWF thinks the Ethereum blockchain may hold the key to better fundraising—but not in the way you're thinking.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, has entered into a research collaboration with Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology at Washington University School of Medicine, to explore the influence of Microbiome Metabolic Therapies (MMT™) on microbial and host physiology and metabolism. Dr. Gordon is considered the founder of the modern microbiome field and is recognized worldwide for his fundamental work in uncovering the underpinnings of the relationships between microorganisms residing in the gut and mammalian physiology. Under the collaboration, gnotobiotic preclinical models will be combined with innovative experimental and computational methods to further identify molecular pathways by which Kaleido’s MMTs can modify the functional configuration of the gut microbiome and its metabolic outputs.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today provided a corporate update and announced financial results for the first quarter 2020. The program aims to enroll a total of approximately 400 patients in two non-IND controlled clinical studies.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production- KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related.
Ms. Mixer has more than 25 years of experience in healthcare and is currently Chief Digital Transformation Officer and Vice President, Strategy at Boston Children’s Hospital. Previously, she launched and ran her own consulting firm, and served for more than a decade as a partner at the Boston Consulting Group. Ms. Mixer has experience across the healthcare industry, including working with executive management and Boards of leading academic medical centers, integrated healthcare delivery networks, payers, pharmacy/PBMs and biopharmaceutical and medical device companies.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health today announced the initiation of a controlled clinical study evaluating Microbiome Metabolic Therapy (MMT) candidate KB109 added to Supportive Self-Care (SSC) for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19. “The burden of the COVID-19 pandemic on patients and healthcare facilities is vast, and there remains a need for interventional studies evaluating patients with mild-to-moderate disease, which represents the majority of infections,” said Katharine Knobil, M.D., Kaleido’s Chief Medical Officer and Head of Research & Development.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019. Mr. Duke brings nearly 20 years of experience in CFO and senior finance roles, including more than a decade within the life sciences industry. “Bill has demonstrated a track record of leadership and corporate finance acumen throughout his career and is experienced in the life sciences industry and capital markets,” said Alison Lawton, President and Chief Executive Officer of Kaleido.
LEXINGTON, Mass., Jan. 06, 2020 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome.
- Results from three clinical studies in 2019 support Phase 2 development program in urea cycle disorders (UCD) and advancement of hepatic encephalopathy program into next.
Is (KLDO) Outperforming Other Medical Stocks This Year?
Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that ex vivo and in vivo data evaluating its Microbiome Metabolic Therapies (MMT™) are being presented at IDWeek 2019™ and the Keystone Symposia on the Microbiome: Therapeutic Implications. Kaleido is advancing MMT candidate, KB109, in clinical development to decrease colonization with multi-drug resistant (MDR) pathogens by selectively enhancing the growth of beneficial bacteria in the gut and reducing the risk of infection.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that it plans to release first quarter 2020 financial results on May 14, 2020 before market open and will host a conference call and webcast at 8:30 a.m. ET that day to provide an update on its platform and pipeline. The live webcast can be accessed in the Investors & Media section of Kaleido’s website at: https://investors.kaleido.com/events-presentations. An archived webcast will be made available on Kaleido’s website shortly after the event and accessible for 90 days.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline ...
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
- Executing Pipeline Towards Key Clinical Data Readouts in Q4 2019 and 2020 - Focusing Resources on Pipeline Programs and Extending Cash Runway LEXINGTON, Mass., Oct. 30,.
The collaboration will explore the potential for Kaleido’s Microbiome Metabolic Therapies (MMT™) to prevent the onset of childhood allergy and other atopic, immune and metabolic conditions by driving specific microbiome features which support an appropriate maturation of the infant immune system. A primary focus of the research will be to utilize Kaleido’s proprietary ex vivo screening platform to identify MMTs candidates that support the growth of specific beneficial microbes.
Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors. Dr. Prener has more than 25 years of leadership experience within life sciences companies, and recently served as Chief Executive Officer (CEO) of Freeline Ltd.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]